Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint®BluePrint® Breast Cancer Kit to Market
Irvine, USA and Rijswijk, Netherlands: 19 December 2017 - Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to provide a secure, convenient, data processing solution for Agendia's MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, which is intended for prognostic use in a clinical setting.
Initially available in Europe, the next-generation sequencing (NGS)-based MammaPrint BluePrint Kit will enable cancer centers to run the test in-house. The partnership with Bluebee enables secure global access to test results, while ensuring all data complies with local data privacy and residency regulations, an essential development in the preparation for the European launch in early 2018.
The MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a binary Low or High Risk-of-cancer recurrence result, while the BluePrint test analyses 80 genes to classify breast cancer into four functional molecular subtypes. Together, the Kit will help physicians personalize treatment management by identifying women who are at a genomic Low Risk for disease recurrence and unlikely to benefit from chemotherapy.
More info on Bluebee's website.
Next > Nexstim enrols last patient in supplementary Phase III E-FIT trial
Previous > Confo Therapeutics enters into drug discovery collaboration with Roche